Related Experiment Videos
m-Hydroxyphenylacetic acid formation from L-dopa in man: suppression by neomycin
Science (New York, N.Y.)
|December 12, 1969
Abstract:
The increased excretion of m-hydroxyphenylacetic acid in the urine of patients with parkinsonism being treated with L-dopa was reduced by gut sterilization with neomycin. The p-de-hydroxylation step is thus brought about solely by the action of gut flora; the pathway is unlikely to be involved in the events within the brain leading to the therapeutic benefit effected by L-dopa.
Insights
Gut bacteria significantly increase m-hydroxyphenylacetic acid excretion in Parkinson's disease patients on L-dopa. Sterilizing the gut with neomycin reduced this excretion, indicating gut flora
Area of Science:
- Neuroscience
- Microbiology
- Pharmacology
Background:
- Parkinson's disease is a neurodegenerative disorder.
- L-dopa is a primary treatment for Parkinson's disease.
- Metabolites of L-dopa can be influenced by gut microbiota.
Purpose of the Study:
- To investigate the role of gut flora in the metabolism of L-dopa.
- To determine if gut bacteria contribute to the increased excretion of m-hydroxyphenylacetic acid (m-HPAA) in Parkinson's patients treated with L-dopa.
Main Methods:
- Patients with Parkinson's disease receiving L-dopa treatment were studied.
- Urine samples were analyzed for m-HPAA levels.
- Gut sterilization was performed using neomycin.
Main Results:
- Increased urinary excretion of m-HPAA was observed in Parkinson's patients on L-dopa.
- Gut sterilization with neomycin significantly reduced the excretion of m-HPAA.
- This suggests the p-de-hydroxylation of L-dopa is primarily mediated by gut flora.
Conclusions:
- The gut microbiome plays a significant role in L-dopa metabolism.
- The observed p-de-hydroxylation pathway is unlikely to be involved in the therapeutic effects of L-dopa in the brain.
- Targeting gut flora may offer novel therapeutic strategies for Parkinson's disease.